Pharmicell Receives Approval for Phase 3 Clinical Trial Plan of Cellgram-LC

[Asia Economy Reporter Oh Ju-yeon] Pharmicell announced on the 3rd that it has received approval from the Korea Ministry of Food and Drug Safety for a multicenter, randomized, open-label, Phase 3 clinical trial plan to evaluate the efficacy and safety of Cellgram-LC administration in patients with alcoholic liver cirrhosis.